IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026
Ipsen has completed its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. This acquisition strengthens Ipsen's late-stage oncology pipeline, representing a strategic expansion of its oncology portfolio.